"He is an experienced senior pharmaceutical and healthcare executive with more than twenty-five years of industry knowledge, and proven accomplishments in the commercialization of primary and specialty pharmaceuticals, strategic and marketing leadership and business development. Alan is well versed in various therapeutic product areas and their respective markets, and he will be a key strategic contributor as Aastrom develops groundbreaking products in the area of human tissue regeneration and moves them toward the marketplace."

Mr. Rubino is currently a Principal with Watchung Partners, a strategic consulting firm to the pharmaceutical, biotech and healthcare industries. Prior to this, Mr. Rubino was the Executive Vice President and General Manager for the Teams Businesses at PDI, Inc., a diversified sales and marketing services provider to the biopharmaceutical, medical devices and diagnostics industries.

Before joining PDI, Mr. Rubino was Senior Vice President of the Pharmaceuticals Technology and Services Division of Cardinal Health. He joined Cardinal Health as part of the acquisition of BLPG, Inc., a healthcare marketing services company, where he was the Executive Vice President and Managing Director. Prior to joining BLPG, Mr. Rubino had a highly distinguished career with Hoffmann-LaRoche (Roche) where he was a member of the U.S. operating and executive committees since 1992. During his tenure at Roche, he held a series of key executive positions in marketing, sales, operations, and human resource management, culminating in the position of Vice President, Business Operations.

Mr. Rubino received a B.A. in economics from Rutgers University with a minor in biology and chemistry, and completed post-graduate work at University of Lausanne and the Harvard Business School. Additionally, Mr. Rubino serves on the Board of Rutgers Business School for both Newark and New Brunswick.

The addition of Mr. Rubino to the Board immediately fills the position vacated by Ms. Linda Fingerle, who has resigned from the Board of Directors to pursue other professional activities. The Company thanks Ms. Fingerle for her contributions and service.

Source Aastrom Biosciences